Rapamycin

Rapamycin (sirolimus) and related mTOR inhibitors have established clinical applications across several therapeutic areas, with ongoing research expanding their potential uses.

Transplant Medicine

Rapamycin is well-established as an immunosuppressive agent in solid organ transplantation. Current research is exploring biomarker-driven precision approaches for its use in lung transplantation, suggesting a move toward more personalized dosing strategies based on mTOR pathway mapping.

Cardiovascular Applications

The drug has significant applications in interventional cardiology through drug-eluting stents. Clinical trials are evaluating rapamycin-eluting bioresorbable coronary stent systems, and temsirolimus (a rapamycin analog) is being studied for adventitial delivery to improve revascularization outcomes in below-the-knee procedures in a Phase 3 trial.

Oncology

Multiple cancer applications are under investigation:

• Triple-negative breast cancer: Completed Phase 1 studies have examined PF-05212384 (an mTOR inhibitor) in combination with other anti-tumor agents and cisplatin
• Familial adenomatous polyposis: A Phase 2 safety study is planned for rapamycin use in children with this hereditary cancer syndrome
• Hematologic malignancies: Phase 1 trials have explored its use in nonmyeloablative stem cell transplantation protocols for indolent lymphoid malignancies, though at least one such study was terminated

Emerging Applications

Research suggests potential therapeutic targets in pulmonary fibrosis through immuno-metabolic reprogramming pathways, though this remains investigational. The mTOR pathway's role in regulating intestinal stem cell activity and autophagy processes is also under study, potentially opening new therapeutic avenues.

Clinical Note: The evidence for some newer applications remains limited to preclinical or early-phase studies. Patients should consult with their healthcare providers about appropriate treatment options for their specific conditions.